SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease
Published: 20 July 2021
1m 20sPart 6 | Session 1 Welcome and Introduction
11m 2sPart 6 | Session 2 How do SGLT2 Inhibitors Bring About Cardiorenal Benefits?
11m 24sPart 6 | Session 3 Totality of Evidence in Heart Failure
11m 20sPart 6 | Session 4 Trial Results Coming Out Soon
10m 55sPart 6 | Session 5 Heart Failure Guidelines
14m 37sPart 6 | Session 6 Panel Discussion
53sPart 1 | Session 1 Welcome and Introduction Stefan Anker, Shelley Zieroth
10m 23sPart 1 | Session 2 SGLT2 Inhibitors for Patients with Diabetes and an Increased CV Risk: How The Success Story Started Bernard Zinman
9m 18sPart 1 | Session 3 SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection Milton Packer
12m 18sPart 1 | Session 4 SGLT2 Inhibitors in Cardiology Indications: The Data John JV McMurray
9m 38sPart 1 | Session 5 SGLT2 Inhibitors in Chronic Kidney Disease: The Data Katherine Tuttle
14m 38sPart 1 | Session 6 Panel Discussion Stefan Anker, Shelley Zieroth, Andrew JS Coats, Bernard Zinman, John JV McMurray, Katherine Tuttle
9m 39sPart 2 | Session 1 Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm Andrew JS Coats
Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders.
The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.
In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities. Audience questions were submitted throughout and were addressed by the panel experts.
SGLT2 Inhibition in Cardiorenal Disease
- Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
- Apply findings from clinical trials into clinical practice
- Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
- Evaluate the safety and cardiorenal benefits of glucose-lowering agents
- Implement the new guidelines of the HFA of the ESC in clinical practice
More from this programme
State of the Art 1
SGLT2 Inhibitors in Heart Failure: A Practical Approach
Meet The Expert: Implications for Clinical Practice - Breakout 1
Meet The Expert: Implications for Clinical Practice - Breakout 2
Meet The Expert: Implications for Clinical Practice - Breakout 3
State of the Art 2
SGLT2 Inhibitors for Heart Failure: The New Standard of Care
Meet The Expert: Implications for Clinical Practice - Breakout 4
Meet The Expert: Implications for Clinical Practice - Breakout 5
Meet The Expert: Implications for Clinical Practice - Breakout 6
Professor of Cardiology
Prof Gerasimos Filippatos is a Professor of Cardiology and Cardiologist at National and Kapodistrian University of Athens, Athens, GR.
He studied Medicine at the University of Patras, and earned his doctorate Cum Laude from the University of Athens.
Prof Filippatos is Past President of the Heart Failure Association (HFA) of the European Society of Cardiology and he has published over 600 articles in peer-reviewed journals and authored more than 30 book chapters.